A Double-Blind, Randomized Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin
Latest Information Update: 08 Nov 2023
At a glance
- Drugs BCD 263 (Primary) ; Nivolumab
- Indications Malignant melanoma; Skin cancer
- Focus Pharmacokinetics
- Sponsors Biocad
Most Recent Events
- 08 Nov 2023 New trial record